Education
About Us
Working with TipRanks
Follow Us
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
Total Valuation
Dianthus Therapeutics has a market cap or net worth of $592.55M. The enterprise value is $624.51M.
Market Cap$592.55M
Enterprise Value$624.51M
Share Statistics
Dianthus Therapeutics has 32,159,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding32,159,980
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Dianthus Therapeutics’s return on equity (ROE) is -0.24 and return on invested capital (ROIC) is -28.62%.
Return on Equity (ROE)-0.24
Return on Assets (ROA)-0.23
Return on Invested Capital (ROIC)-28.62%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee79.94K
Profits Per Employee-1.09M
Employee Count78
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Dianthus Therapeutics is -8.78. Dianthus Therapeutics’s PEG ratio is 0.55.
PE Ratio-8.78
PS Ratio0.00
PB Ratio2.05
Price to Fair Value2.12
Price to FCF-8.11
Price to Operating Cash Flow-8.62
PEG Ratio0.55
Income Statement
In the last 12 months, Dianthus Therapeutics had revenue of 6.24M and earned -84.97M in profits. Earnings per share was -2.48.
Revenue6.24M
Gross Profit5.82M
Operating Income-101.86M
Pretax Income-84.97M
Net Income-84.97M
EBITDA-101.86M
Earnings Per Share (EPS)-2.48
Cash Flow
In the last 12 months, operating cash flow was -78.19M and capital expenditures -97.00K, giving a free cash flow of -78.10M billion.
Operating Cash Flow-78.19M
Free Cash Flow-78.10M
Free Cash Flow per Share-2.43
Dividends & Yields
Dianthus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.18
52-Week Price Change-15.97%
50-Day Moving Average19.40
200-Day Moving Average23.76
Relative Strength Index (RSI)41.21
Average Volume (3m)281.83K
Important Dates
Dianthus Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Dianthus Therapeutics as a current ratio of 15.22, with Debt / Equity ratio of 0.42%
Current Ratio15.22
Quick Ratio15.22
Debt to Market Cap<0.01
Net Debt to EBITDA0.21
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Dianthus Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Dianthus Therapeutics EV to EBITDA ratio is -7.12, with an EV/FCF ratio of -9.26.
EV to Sales116.29
EV to EBITDA-7.12
EV to Free Cash Flow-9.26
EV to Operating Cash Flow-9.27
Balance Sheet
Dianthus Therapeutics has $263.23M in cash and marketable securities with $1.40M in debt, giving a net cash position of -$261.83M billion.
Cash & Marketable Securities$263.23M
Total Debt$1.40M
Net Cash-$261.83M
Net Cash Per Share-$8.14
Tangible Book Value Per Share$10.30
Margins
Gross margin is 79.28%, with operating margin of -1633.74%, and net profit margin of -1362.77%.
Gross Margin79.28%
Operating Margin-1633.74%
Pretax Margin-1362.77%
Net Profit Margin-1362.77%
EBITDA Margin-1633.74%
EBIT Margin-1633.74%
Analyst Forecast
The average price target for Dianthus Therapeutics is $43.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$43.83
Price Target Upside137.95% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast189.31%
EPS Growth Forecast51.03%